Sign In
Buy PBYI
$8.04
+0.380 (+4.96%)
At Close: Jun 23, 2026
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:33pm, Wednesday, 04'th Jun 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2025, the Compensation Committee of Puma's Board of Directors approved the
Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors
09:51am, Wednesday, 28'th May 2025
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Puma Biotech (PBYI) could be a great choice. It is one of the several stocks that pa
Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now?
10:46am, Monday, 26'th May 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock
09:50am, Monday, 12'th May 2025
Puma Biotech (PBYI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks th
Is Puma Biotechnology (PBYI) Stock Undervalued Right Now?
10:46am, Friday, 09'th May 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates
09:50am, Friday, 09'th May 2025
Puma Biotechnology PBYI reported first-quarter 2025 adjusted earnings of 10 cents per share, which beat the Zacks Consensus Estimate of 2 cents. In the year-ago quarter, the company had incurred a los
Puma Biotechnology, Inc. (PBYI) Q1 2025 Earnings Call Transcript
09:08am, Friday, 09'th May 2025
Puma Biotechnology, Inc. (NASDAQ:PBYI ) Q1 2025 Results Conference Call May 8, 2025 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director Investor Relations Alan Auerbach - President & C
Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates
07:00pm, Thursday, 08'th May 2025
Puma Biotech (PBYI) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to loss of $0.05 per share a year ago.
Puma Biotechnology Reports First Quarter Financial Results
04:05pm, Thursday, 08'th May 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology release its 1Q'25 earnings results on May 8 after markets closed and followed with a conference call to discuss operating results.
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05:15pm, Tuesday, 06'th May 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation Committee of Puma's Board of Directors approved the
Puma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should Know
01:00pm, Wednesday, 30'th Apr 2025
Puma Biotech (PBYI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients
06:00am, Wednesday, 30'th Apr 2025
ATHENS, Greece and LOS ANGELES, April 30, 2025 (GLOBE NEWSWIRE) -- Er-Kim, an international pharmaceutical company specializing in the commercialization of novel therapies in the EMEA region, today an
Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025
03:03pm, Monday, 28'th Apr 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced Phase I data of trastuzumab deruxtecan plus neratinib in solid tumors with HER2 alterations was presented at AACR 2025.
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results
04:11pm, Thursday, 24'th Apr 2025
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 1Q-2025 results after market close on May 8, 2025, and follow with a conference call at 1:30 pm PT/4:30 pm ET.
Should Value Investors Buy Puma Biotechnology (PBYI) Stock?
10:45am, Wednesday, 23'rd Apr 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
